Evopoint Biosciences (SH.688837) is an innovation-driven biopharmaceutical company with a clear mission: to translate cutting-edge science into transformative therapies for patients with significant unmet medical needs. We are dedicated to developing and delivering best-in-class treatments that profoundly impact the lives of patients worldwide.
Driven by three core technology platforms— Small Molecule Drug Discovery Platform, Novel Antibody Discovery Platform, and Targeted Protein Degradation Platform—Evopoint has established a deep strategic presence in high-impact disease areas, including precision oncology and multidrug-resistant (MDR) infections. Our innovation engine is delivering tangible results: multiple pipeline assets have advanced to Phase III trials or the NDA stage, repeatedly securing Breakthrough Therapy and Fast Track designations from both the NMPA and FDA. The strength of our clinical data is further validated by significant global recognition, leading to landmark licensing and collaboration agreements with renowned pharmaceutical partners, with a total deal value exceeding $2 billion. Looking forward, we are building a fully integrated, end-to-end ecosystem spanning from discovery and clinical development to manufacturing and global commercialization. Evopoint is firmly on a path to becoming a world-class, globally recognized biopharmaceutical leader.
Evopoint, Inspiring Innovation, Improving Lives.
Pipeline
Partnering
Investor
